Correspondence

Correction

Clarification of Funding of Early Lung Cancer Study

N Engl J Med 2008; 358:1862April 24, 2008

Article

To the Editor:

In our article1 published in the October 26, 2006, issue of the Journal, one of the disclosed sources of funding was the Foundation for Lung Cancer: Early Detection, Prevention and Treatment, which provided partial support for our research. For full transparency we wish to inform you that $3.6 million (virtually all of the Foundation's funding) was contributed in 2000 through 2003 as an unrestricted gift by the Vector Group, the parent company of Liggett Tobacco, which manufactures cigarettes.

Claudia Henschke, Ph.D., M.D.
Weill Medical College of Cornell University, New York, NY 10021
chensch@med.cornell.edu

This letter (10.1056/NEJMc086128) was published at www.nejm.org on April 2, 2008.

1 References

1. 1

   The International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771
   Full Text | Web of Science | Medline

Citing Articles (4)

Citing Articles

1. 1

   F. Eisinger. (2010) Recherche et multiplicité des conflits d’intérêts. Oncologie 12:11-12, 671-674
   CrossRef

2. 2

   David B. Resnik. (2009) Perspective: Disclosing Hidden Sources of Funding. Academic Medicine 84:9, 1226-1228
   CrossRef

3. 3

   David B. Resnik. (2008) Hidden Sources of Private Industry Funding. The American Journal of Bioethics 8:8, 60-61
   CrossRef

4. 4

   Schwartz, Robert S., Curfman, Gregory D., Morrissey, Stephen, Drazen, Jeffrey M., . (2008) Full Disclosure and the Funding of Biomedical Research. New England Journal of Medicine 358:17, 1850-1851
   Full Text